Virtual care, health-system software, and consumer health platforms.
Components that cannot be computed are dropped and the weights renormalize — never faked to neutral.
Undisclosed amounts count as zero capital; deals still count.
| # | Company | Valuation | Secondary vs Round | Last Round |
|---|---|---|---|---|
| 1 | Neuralink | $15B as of 2025-Q2 | no mark | 2025-06-01 |
| 2 | Devoted Health | $13B as of 2023-Q4 | -36.9% | 2026-01-30 |
| 3 | Biosplice Therapeutics | $12B as of 2018-Q3 | no mark | 2018-08-15 |
| 4 | OpenEvidence | $12B as of 2026-Q1 | -6.8% | 2026-01-21 |
| 5 | Ro | $7.0B as of 2025 | no mark | 2022-02-22 |
| 6 | Commure | $7.0B as of 2026-05 | no mark | undated |
| 7 | WeDoctor | $6.9B as of 2020-Q4 | no mark | 2020-12-17 |
| 8 | Ro Health | $6.6B as of 2022-Q1 | -64.4% | 2022-01-12 |
| 9 | Doctolib | $6.5B as of 2022-Q1 | no mark | 2022-03-14 |
| 10 | Cityblock | $6.3B as of 2021-Q3 | -89.0% | 2021-09-02 |
| 11 | Lark | $6.0B as of 2026-05 | -74.1% | 2024-09-30 |
| 12 | Abridge | $5.7B as of 2025-Q2 | +15.2% | 2025-06-23 |
Methodology. Emerging Spaces groups the tracked private-company roster into curated thematic spaces and scores each space's momentum 0–100 from four disclosed-data components: trailing-90-day capital vs the prior 90 days (40%), deal-count acceleration on the same windows (25%), news activity per tracked company over 30 days (20%), and the median secondary-market premium to last round across the space's marked names (15%). Components that cannot be computed are dropped and the weights renormalize — the basis is disclosed per space. Quarterly trends derive from dated, disclosed rounds; undisclosed amounts count as zero capital. An attention map of disclosed activity — not a prediction, not investment advice.